Association between antihypertensive drug use and hypoglycemia: A case- control study of diabetic users of insulin or sulfonylureas

Clinical Therapeutics

Volumn 21, Issue 8, 1999, Pages 1387-1400

  Thamer, Mae ^a,d,e   Ray, Nancy F ^b   Taylor, Terry ^c  

^a Med Technol Pract Patterns Inst   (United States)

^b Medicare Payment Advisory Commission   (United States)

^c BAYER CORPORATION   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ACE inhibitors; Antihypertensives; Diabetes; Hypertension; Hypoglycemia; blockers

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLUCAGON; INSULIN; LISINOPRIL; QUINAPRIL; RAMIPRIL; SALICYLIC ACID; SULFONYLUREA DERIVATIVE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; RISK FACTOR;

EID: 0032842287     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80039-3     Document Type: Article

References (40)

1. American Diabetes Association. Treatment of hypertension in diabetes. Diabetes Care. 1993;16:1394-1401.
2. The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
3. Kaplan NM, Rosenstock J, Raskin P. A differing view of treatment of hypertension in patients with diabetes mellitus. Arch Intern Med. 1987;147:1160-1162.
4. Raskin R. How to treat hypertension in diabetic patients. Postgrad Med. 1988;83:213-232.
5. American Diabetes Association. Clinical practice recommendations 1999. Diabetes Care. 1999;22(Suppl 1):S66-S69.
6. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med. 1993;153:2426-2435.
7. Yokoyama H, Tomonaga O, Hirayamia M, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia. 1977;40:405-411.
8. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-945.
9. Materson BJ. ACE inhibitors as a shield against diabetic nephropathy. Arch Intern Med. 1996;156:239-240.
10. Steffes MW. Diabetic nephropathy: Incidence, prevalence, and treatment. Diabetes Care. 1997;20:1059-1060.
11. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080-1084.
12. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing the risk of macrovascular complications in type 2 diabetes. Br Med J. 1998;317:713-720.
13. Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:1415-1427.
14. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
15. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
16. Lithell H, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: Influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol. 1990;15(Suppl 5): S46-S52.
17. Shorr RI, Ray WA, Daugherty JR, Griffin MR, Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997; 278:40-43.
18. Herings RM, de Boer A, Stricker BH, et al. Hypoglycemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 1995;345:1195-1198.
19. Aruaz-Pachecho C, Ramirez LC, Rios JM, Ruskin P. Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. Am J Med. 1990;89:811-812.
20. McMurray J, Fraser DM. Captopril, enalapril, and blood glucose. Lancet. 1986;1(8488):1035.
21. Washio M, Onoyama K, Makita Y, et al. Hypoglycemia associated with the administration of angiotensin-converting enzyme inhibitor in a diabetic hemodialysis patient. Nephron. 1991;59:341-342.
22. Bell DSH. Hypoglycemia induced by enalapril in patients with insulin resistance and NIDDM. Diabetes Care. 1992;15:934-936.
23. Rett K, Wicklmayer M, Dietze GJ. Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril. N Engl J Med. 1988;319:1609.
24. Ferriere M, Lachkar H, Richard JL, et al. Captopril and insulin sensitivity. Ann Intern Med. 1985;102:134-135.
25. The Fifth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1993;153:154-183.
26. Department of Health and Human Services. International Classification of Diseases, Ninth Revision, Clinical Modification. 2nd ed. Washington, DC: US Government Printing Office; 1980.
27. Seltzer HS. Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am. 1989;18:163-183.
28. US Bureau of Labor Statistics. Consumer Price Index for Hospital and Related Services, Physician Services, Professional Medical Services, Drugs, and Medical Care Commodities. Washington, DC: US Department of Labor; 1996.
29. Barnett AH, Leslie D, Watkins PJ. Can insulin-treated diabetics be given beta-adrenergic blocking drugs? Br Med J. 1980;280:976-978.
30. Donnelly R. Angiotensin-converting enzyme inhibitors and insulin sensitivity: Metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol. 1992;20(Suppl 11):S38-S44.
31. Kerr D, MacDonald IA, Heller SR, Tattersall RB. Beta-adrenoceptor blockade and hypoglycemia, A randomized, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol. 1990;29:685-693.
32. Chan JCN, Cockram CS, Critchley JH. Drug-induced disorders of glucose metabolism: Mechanisms and management. Drug Saf. 1996;2:135-157.
33. Turnbridge WMG. Factors contributing to deaths of diabetics under fifty years of age. Lancet. 1981;2:569-572.
34. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia. 1978;41:363-370.
35. Frier BM. Hypoglycemia and diabetes. Diabetic Med. 1986;3:513-525.
36. Ray NF, Thamer M, Gardner E, Chan JK. Economic consequences of diabetes mellitus in the United States in 1997. Report of the American Diabetes Association. Diabetes Care. 1998;21:296-308.
37. American Diabetes Association. Clinical practice recommendations 1999. Diabetes Care. 1999;22(Suppl 1):S103-S104.
38. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998;339:875-882.
39. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257-263.
40. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363-369.